- Home
- ELVN vs BCSF Comparison
ELVN vs BCSF Comparison
Compare ELVN & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- BCSF
- Stock Information
- Founded
- ELVN 2016
- BCSF 2015
- Country
- ELVN United States
- BCSF United States
- Employees
- ELVN N/A
- BCSF N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- ELVN Health Care
- BCSF Finance
- Exchange
- ELVN Nasdaq
- BCSF Nasdaq
- Market Cap
- ELVN 1.1B
- BCSF 1.2B
- IPO Year
- ELVN 2020
- BCSF 2018
- Fundamental
- Price
- ELVN $16.53
- BCSF $14.96
- Analyst Decision
- ELVN Strong Buy
- BCSF Hold
- Analyst Count
- ELVN 4
- BCSF 4
- Target Price
- ELVN $39.25
- BCSF $17.25
- AVG Volume (30 Days)
- ELVN 359.8K
- BCSF 443.2K
- Earning Date
- ELVN 05-13-2025
- BCSF 05-05-2025
- Dividend Yield
- ELVN N/A
- BCSF 0.80%
- EPS Growth
- ELVN N/A
- BCSF N/A
- EPS
- ELVN N/A
- BCSF 1.85
- Revenue
- ELVN N/A
- BCSF $292,653,000.00
- Revenue This Year
- ELVN N/A
- BCSF N/A
- Revenue Next Year
- ELVN N/A
- BCSF N/A
- P/E Ratio
- ELVN N/A
- BCSF $8.09
- Revenue Growth
- ELVN N/A
- BCSF N/A
- 52 Week Low
- ELVN $13.30
- BCSF $13.20
- 52 Week High
- ELVN $30.03
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- ELVN 40.34
- BCSF 40.53
- Support Level
- ELVN $15.49
- BCSF $13.78
- Resistance Level
- ELVN $18.14
- BCSF $15.08
- Average True Range (ATR)
- ELVN 1.93
- BCSF 0.68
- MACD
- ELVN -0.17
- BCSF -0.01
- Stochastic Oscillator
- ELVN 41.09
- BCSF 48.62
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.